Loading…
← CockpitCompetitor Analysis › CGON CG Oncology, Inc.Open in the cockpit ↗

CG Oncology, Inc.CGONCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Biotech developing cretostimogene, an oncolytic virus immunotherapy for non-muscle invasive bladder cancer.

Momentum leader 88
Mkt cap
$7.15B
US dollars, full cap
Free float
67%
of shares outstanding
$/day
$137M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.8%
Hurdle
n/a
no reverse DCF
Next earnings
128 days
26 Mar 2027
Close · USD$80.00
1D+1.3%
1W+10.2%
1M+29.2%
3M+3.1%
6M+23.5%
YTD+92.7%
1Y+93.9%
ATR %7.3%
Beta0.87
52w lowhigh14.8% off high

What CG Oncology does

Biotech developing cretostimogene, an oncolytic virus immunotherapy for non-muscle invasive bladder cancer.

Has no product to sell yet, so its spending is funded by investors' money, including its 2024 stock-market listing, not by customers. Everything rests on one drug, cretostimogene, a virus engineered to infect and kill bladder tumour cells, and on regulatory approval of it.

Products and services

  • Cretostimogene grenadenorepvec (bladder cancer, pipeline)

Customers

  • Urologists/oncologists treating bladder cancer (pe

Where it sits in the supply chain

  • Healthcare
  • Biotechnology
  • Oncolytic virus immunotherapy discovery…

What could go right

  • Potential best-in-class efficacy/durability data
  • Approval and launch in an underserved bladder-cancer niche

What could go wrong

  • Pre-revenue, single-asset concentration risk
  • Regulatory/manufacturing risk for a novel viral therapy

Moat: narrow (IP / patents). A differentiated oncolytic-virus mechanism showing strong trial responses in a disease area with limited good options.

Headquarters: Irvine, California, US · Founded: 2019 · Employees: 142

Named competitors

CG Oncology at a glance

Size CG Oncology (CGON) is a United States Health Care company (Biotechnology) with a market value of $7.15B, the 948th largest of 3,085 United States companies the cockpit tracks. Shares closed at $80.00 on 18 Nov 2026.

Performance Over six months the shares gained 23.5%, against +1.8% for the median peer and -2.2% for the United States market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 183.6% over the last twelve months (peer median +18.9%); the operating margin is -4,293.5% (peer median -11.5%).

Valuation It trades at 1,000.7× enterprise value to sales against a peer median of 14.0× (3rd most expensive of 16).

Short interest Short interest is 10.3% of the free float (30 Oct 2026).

Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026CGON 124Peer median 102
Six months, rebased to 100: CG Oncology against the median of its 20 peers (local-currency closes).

CG Oncology financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$6.17M$4.04M$1.14M$204,000$191,000
Revenue growth—+255%+458%+7%—
Gross profit-$6.55M-$652,000$1.11M$187,000$176,000
EBITDA-$261M-$189M-$115M-$55.4M-$35.2M
Net income-$237M-$161M-$88.0M-$48.6M-$35.4M
Free cash flow-$189M-$132M-$78.9M-$45.7M-$29.8M
Capital expenditure$1.89M$134,000$234,000$0$14,000
Total debt$9.24M$7.02M$238,000$826,000$16.3M

Quarterly statements and history in the cockpit →

CG Oncology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%AXSMIMVTTXGTWSTKODARWRSMMT1548SRRK196170CAIANTHEMPCVXKRYS300122002422KYMR300347COGTDNTHCGON6-month return →1-month return →
Up and to the right = strong over both horizons. CG Oncology is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×500×1,000×1,500×AXSMTXGTWSTARWR1548ANTHEMKRYS300122KYMRDNTHCGONRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. CG Oncology is the large dot.

CG Oncology competitors and peer comparison

Head to head with its named competitors (CGON vs MRK vs IBRX vs JNJ)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
CG Oncology CGON$7.15B+24%+184%-4,294%1,000.7×n/a
Merck & MRK$340B+23%+5%18%5.7×8.3%
ImmunityBio IBRX$7.13B-17%+121%-150%44.3×n/a
Johnson & Johnson JNJ$656B+20%+8%26%6.9×3.7%
UroGen Pharma URGN$1.46B-1%+159%-12%6.3×n/a

How CG Oncology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

CG Oncology against its 20 peers (data as of 18 Nov 2026)
MeasureCGONPeer medianRank in peer set
1-month return+29.2%-9.3%highest of 21
6-month return+23.5%+1.8%9th highest of 21
Distance from 52-week high-14.8%-34.3%3rd highest of 21
Revenue growth (TTM)+183.6%+18.9%highest of 15
Operating margin-4,293.5%-11.5%3rd lowest of 16
EV / Sales1,000.7×14.0×3rd most expensive of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
CG Oncology CGONUnited States$7.15B+24%+184%-4,294%1,000.7×n/an/a
Axsome Therapeutics AXSMUnited States$7.05B-42%+54%-19%8.0×n/an/a
Immunovant IMVTUnited States$6.86B-7%n/an/an/an/an/a
10x Genomics TXGUnited States$7.51B+138%-4%-11%11.3×47.2%+16.6%
Twist Bioscience TWSTUnited States$7.93B+117%+22%-29%16.2×n/an/a
Kodiak Sciences KODUnited States$6.40B+170%n/an/an/an/an/a
Arrowhead Pharmaceuticals ARWRUnited States$6.09B-44%-46%-157%14.0×n/an/a
Summit Therapeutics SMMTUnited States$8.40B-41%n/an/an/an/an/a
Genscript Biotech 1548.HKHong Kong$8.69B+133%+53%12%9.8×36.9%+19.8%
Scholar Rock SRRKUnited States$5.86B-1%n/a-71,732%9,900.4×n/an/a
ALTEOGEN 196170.KSSouth Korea$8.80B-56%+61%53%35.1×24.6%+38.5%
Caris Life Sciences CAIUnited States$5.59B+24%+61%13%5.0×18.2%+61.5%
Anthem Biosciences ANTHEM.NSIndia$5.51B+16%-1%35%24.9×36.9%+26.2%
Vaxcyte PCVXUnited States$9.26B+24%n/an/an/an/an/a
Krystal Biotech KRYSUnited States$9.34B+4%+26%48%18.0×13.1%+26.0%
Chongqing Zhifei Biological Products 300122.SZChina$5.28B-1%-28%-210%5.3×-6.5%-10.0%
Sichuan Kelun Pharmaceutical 002422.SZChina$10.1B+35%0%9%3.7×6.2%+2.3%
Kymera Therapeutics KYMRUnited States$10.3B+50%+134%-396%92.4×n/an/a
Hangzhou Tigermed Consulting 300347.SZChina$4.88B-2%+16%10%4.8×25.9%+16.4%
Cogent Biosciences COGTUnited States$4.84B-16%n/an/an/an/an/a
Dianthus Therapeutics DNTHUnited States$4.73B-5%-12%-8,684%1,432.1×n/an/a

Questions

Who are CG Oncology's main competitors?
Named competitors: Merck & Co. (Keytruda in bladder cancer) (MRK), Ferring Pharmaceuticals (Adstiladrin) (private or unlisted), ImmunityBio (IBRX), Johnson & Johnson (JNJ), UroGen Pharma (URGN), enGene Holdings (private or unlisted). The cockpit's measured peer set (industry) also includes Axsome Therapeutics (AXSM), Immunovant (IMVT), 10x Genomics (TXG), Twist Bioscience (TWST), Kodiak Sciences (KOD), Arrowhead Pharmaceuticals (ARWR).
Is CG Oncology expensive compared with its peers?
On ev / sales it trades at 1,000.7× against a peer median of 14.0×, 3rd most expensive of 16 in its peer set.
How has CG Oncology stock performed?
Over six months to 18 Nov 2026 the shares returned +23.5% against +1.8% for the median peer; over one year +93.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.